About Us
Our Business
Investors
Media
Community
Sustainability
Careers
Contact
Menu
India
USA
UK
South Africa
Australia
Philippines
Germany
Netherlands
Mexico
Brazil
Canada
Switzerland
Close
About Us
Overview
The Lupin Story
Our Purpose
Our Values
Our Leadership
Compliance, Ethics and Governance
Global Presence
Our Manufacturing Approach
Quality in Action
Our Science
Awards and Recognitions
Our Business
Overview
Global Generics
Emerging Markets
India
Specialty and Innovation
Biosimilars
Our Adjacencies
Investors
Overview
Financial Reporting
Financial Information
Quarterly Results
Integrated Report
Financial Statements of Subsidiaries
Corporate Governance
Our Leadership
Committees of the Board
Code of Conduct
Policies
MOA and AOA
Shareholder Information
Stock Exchange Intimations
AGM, Postal Ballot, and EGM
Shareholding Pattern
Share Price
Ratings
Dividend
Unclaimed Dividend and Shares
Employee Stock Option Schemes
Important Communication for Shareholders
Investor FAQs
Investor Contacts
News and Events
Press Releases
Presentations
Disclosure Under Regulation 46 of SEBI (LODR) Regulations, 2015
Media
Overview
Press Releases
Media Coverage
Perspectives
Media Kit
Community
Sustainability
Overview
ESG Framework
ESG Goals and Progress
Key Highlights
ESG Ratings
ESG Governance
Careers
Contact
About Us
Our Business
Investors
Media
Community
Sustainability
Careers
Contact
Overview
The Lupin Story
Our Purpose
Our Values
Our Leadership
Compliance, Ethics and Governance
Global Presence
Our Manufacturing Approach
Quality in Action
Our Science
Awards and Recognitions
+91 22 6640 2323
info@lupin.com
News and
Events
Press Releases
Presentations
Press Releases
Select Year
August 20, 2026
Press
Releases
Lupin and Tenpoint Therapeutics Announce Strategic Partnership to Commercialize YUVEZZI™ in the European Union, the United Kingdom, Switzerland, Norway, and Iceland
August 17, 2026
Press
Releases
Lupin Announces Approval from U.S. FDA for Pitolisant Tablets
August 10, 2026
Press
Releases
Lupin Announces the Approval of Sodium Zirconium Cyclosilicate for Oral Suspension in the United States
August 6, 2026
Press
Releases
Lupin Q1 FY2027 Results
July 31, 2026
Press
Releases
Lupin Announces the Approval of Diazepam Injection, USP in the United States
July 31, 2026
Press
Releases
Lupin Announces U.S. FDA Approval and Launch of Sugammadex Injection
1
2
3
4
5
...
114
Next
Product Finder
